Sign in
or
Register
0
Add listing
View all results
No results
News
Events
The industry
arrow_drop_down
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Networking platforms
Newsletter
Association
arrow_drop_down
Mission and services
Members
Academy
Partners
Team
Media
Add listing
Relugolix + E2/NETA
Product
prev
next
Leave a review
Bookmark
Share
Report
prev
next
Indicaton
Heavy menstrual bleeding associated with uterine fibroids.
Therapeutic indications
Women’s health
Type of product
Small molecule
Company
Myovant Sciences GmbH
Table
Phase
Phase III completed
You may also be interested in
Relugolix + E2/NETA
Endometriosis-associated pain.
Phase III started
TOP-N53, TOP-N44, TOP-M119, TOP-V122, TOP-T5
Clinical development for diabetic foot ulcer and digital ulcer. Preclinical development burn wounds, normal tension glaucoma, hair growth and chemotherapy induced hair loss, prevention of colorectal cancer, Elimination of cancer stem cells and skin aging.
Phase I started
DCVAC/OvCa
Ovarian cancer
Phase II completed
Cart
×
View all results
No results
Facebook
Twitter
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
VKontakte
Mail
Copy link
This site uses cookies:
Find out more.
Accept